Glucosamine Does Not Increase Dementia Risk
Based on the highest quality recent evidence, glucosamine supplementation does not increase the risk of dementia in older adults with mild cognitive impairment—in fact, it may be protective against certain dementia subtypes, particularly vascular dementia.
Evidence Summary
The most robust and recent research directly addressing this question comes from multiple large-scale studies published in 2023-2024:
Protective Association Found
A 2023 UK Biobank study of 214,945 participants over age 60 found that habitual glucosamine use was associated with an 18% lower risk of vascular dementia (adjusted HR 0.82,95% CI 0.70-0.96) over 12 years of follow-up 1. Importantly, this study found no significant association with Alzheimer's disease (HR 1.02) or frontotemporal dementia (HR 0.95), indicating the protective effect is specific to vascular dementia rather than a general dementia risk increase.
A separate 2023 study combining observational cohort analysis with Mendelian randomization found glucosamine users had a 16% lower risk of all-cause dementia (HR 0.84,95% CI 0.75-0.93), 17% lower risk of Alzheimer's disease (HR 0.83), and 26% lower risk of vascular dementia (HR 0.74) 2. The Mendelian randomization analysis—which reduces confounding—supported a causal protective relationship.
No Association Confirmed
The largest and most recent study from 2024, analyzing approximately 290,000 UK Biobank participants with median follow-up of 9-10 years, found no association between glucosamine supplementation and incident dementia (HR 1.06,95% CI 0.99-1.14) or Parkinson's disease (HR 0.97,95% CI 0.86-1.09) 3. This study used multiple dietary surveys to confirm habitual use patterns.
Important Contextual Finding
A 2026 study examining electronic health records found that while glucosamine records were associated with faster MCI-to-dementia progression, similar associations were observed for multivitamin and calcium/vitamin D records 4. This suggests the association reflects documentation patterns or confounding factors rather than a glucosamine-specific harmful effect.
Clinical Interpretation
Key Points for Practice:
- No evidence supports glucosamine increasing dementia risk in older adults with MCI
- The preponderance of evidence suggests either neutral or potentially protective effects, particularly for vascular dementia
- The APOE ε4 genotype does not modify this relationship 1
- Any protective effect appears more pronounced in those under 60 years 2
Important Caveats:
- Confounding by indication: People taking glucosamine may have different health behaviors, socioeconomic status, or healthcare engagement patterns
- Supplement quality variability: Studies relied on self-reported use without verification of product quality or actual consumption
- Observational limitations: Despite Mendelian randomization support, definitive causality requires randomized controlled trials
Guideline Context
While the diabetes care guidelines 5, 6, 5 emphasize screening older adults for cognitive impairment and note that various interventions (cholinesterase inhibitors, glutamatergic antagonists) have not shown benefit for preventing cognitive decline, glucosamine is not mentioned as a risk factor for dementia in any major clinical guidelines.
The guidelines consistently note that cognitive decline in older adults is multifactorial, related to glycemic control, hypoglycemia, and vascular risk factors—but do not identify glucosamine as a concern.
Bottom Line
You can reassure patients that glucosamine supplementation does not increase dementia risk. The evidence suggests it may actually provide modest protection against vascular dementia, though this requires confirmation through randomized trials. For older adults with MCI taking glucosamine for joint health, there is no cognitive safety concern warranting discontinuation based on current evidence.